The Drug Controller General of India (DCGI) has declined the proposal of pharma company Dr Reddy’s Laboratories to conduct Phase 3 trials for Sputnik V. Instead of jumping straight to a large-scale trial, Dr Reddy’s has been advised to consider a small trial first.
Russia has held Phase 3 trials for the vaccine since 1 September on around 40,000 subjects. However, according to the Subject Expert Committee which looked into Dr Reddy’s proposal, “the safety and immunogenicity data in overseas Phase I/II studies is small and there is no data available on Indian subjects”. “After detailed deliberation, the committee recommended that the firm should follow the regulatory requirements and conduct Phase II/ III clinical trial in the country with proper monitoring for humoral & cell-mediated immune response,” it further said. The committee has also said that the firm should submit the protocol for the consideration of the committee.
Thousands gathered in Tel Aviv as three hostages, held for 471 days by Hamas, were…
Vivian Dsena secured the first runner-up spot, while Rajat Dalal was named the second runner-up.
Over 80 deaths and 5,000 displacements were reported in Colombia’s Catatumbo region due to escalating…
Biden hailed a ceasefire in Gaza, marking his last day in office. He praised the…
Biden marked his final day by reflecting on hope and resilience, delivering a poignant speech…
Scholz emphasizes Holocaust remembrance and combats normalization of hate speech as far-right movements gain traction…